

Susan M O'brien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3583897/publications.pdf>

Version: 2024-02-01

129
papers

22,298
citations

20759

60
h-index

16605

123
g-index

130
all docs

130
docs citations

130
times ranked

13597
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 32-42.	13.9	2,019
2	Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2014, 370, 997-1007.	13.9	1,535
3	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	13.9	1,427
4	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	0.6	1,069
5	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 740-753.	13.9	1,047
6	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 57-66.	5.1	1,031
7	Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4079-4088.	0.8	899
8	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	13.9	785
9	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood</i> , 2015, 125, 2497-2506.	0.6	618
10	The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. <i>Blood</i> , 2012, 119, 1182-1189.	0.6	564
11	Ibrutinib+Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2019, 381, 432-443.	13.9	545
12	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 303-309.	0.6	441
13	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 48-58.	5.1	438
14	Inotuzumab ozogamicin, an anti-CD22+calcetamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 403-411.	5.1	401
15	Chronic lymphocytic leukaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 16096.	18.1	363
16	Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3880-3889.	0.8	361
17	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. <i>Blood</i> , 2018, 131, 1910-1919.	0.6	339
18	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	2.0	305

#	ARTICLE	IF	CITATIONS
19	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. <i>Blood</i> , 2015, 125, 2062-2067.	0.6	303
20	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. <i>Blood</i> , 2017, 129, 572-581.	0.6	285
21	Management of adverse events associated with idelalisib treatment: expert panel opinion. <i>Leukemia and Lymphoma</i> , 2015, 56, 2779-2786.	0.6	268
22	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3441-3452.	0.8	266
23	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 2728-2736.	2.0	265
24	Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. <i>Blood</i> , 2016, 127, 1863-1869.	0.6	253
25	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. <i>Blood</i> , 2014, 123, 1810-1817.	0.6	246
26	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 1547-1555.	5.1	245
27	A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 2686-2694.	0.6	224
28	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. <i>Cancer</i> , 2015, 121, 3612-3621.	2.0	220
29	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. <i>Blood</i> , 2017, 129, 1275-1283.	0.6	214
30	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-CVATE study. <i>Cancer</i> , 2019, 125, 2474-2487.	2.0	210
31	Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 904-910.	0.8	203
32	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017, 102, 1796-1805.	1.7	200
33	Duvelisib, a novel oral dual inhibitor of PI3K- $\hat{1}$, $\hat{2}$, $\hat{3}$, is clinically active in advanced hematologic malignancies. <i>Blood</i> , 2018, 131, 877-887.	0.6	199
34	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 240-248.	5.1	192
35	Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 2820-2822.	0.8	182
36	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 1011-1019.	0.6	168

#	ARTICLE	IF	CITATIONS
37	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. <i>Lancet Haematology</i> , 2017, 4, e387-e398.	2.2	158
38	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 1524-1533.	1.7	154
39	Monoclonal antibodies in acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 4010-4016.	0.6	144
40	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>Journal of Clinical Oncology</i> , 2017, 35, 166-174.	0.8	131
41	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. <i>Leukemia and Lymphoma</i> , 2015, 56, 1643-1650.	0.6	130
42	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	0.6	130
43	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016, 127, 1269-1275.	0.6	119
44	Evolution of CLL treatment from chemoimmunotherapy to targeted and individualized therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 510-527.	12.5	114
45	Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. <i>Cancer</i> , 2008, 113, 2097-2101.	2.0	109
46	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. <i>Cancer</i> , 2010, 116, 5568-5574.	2.0	104
47	Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. <i>Cancer</i> , 2017, 123, 2268-2273.	2.0	103
48	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 392-400.	1.2	102
49	Long-term outcomes for ibrutinib+rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. <i>Blood</i> , 2022, 140, 112-120.	0.6	93
50	Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). <i>Cancer</i> , 2014, 120, 3660-3668.	2.0	91
51	Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options. <i>Current Oncology Reports</i> , 2012, 14, 387-394.	1.8	83
52	Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, rituximab, cyclophosphamide) or related regimens. <i>Blood</i> , 2010, 116, 5568-5574.	0.6	83
53	Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. <i>Blood</i> , 2009, 113, 3168-3171.	0.6	82
54	Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. <i>Journal of Clinical Apheresis</i> , 1995, 10, 188-193.	0.7	75

#	ARTICLE	IF	CITATIONS
55	Hyper-FCVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	2.0	74
56	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 294-302.	2.0	70
57	Initial treatment of CLL: integrating biology and functional status. <i>Blood</i> , 2015, 126, 463-470.	0.6	69
58	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018, 93, 371-374.	2.0	68
59	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	2.2	66
60	Targeted therapies for CLL: Practical issues with the changing treatment paradigm. <i>Blood Reviews</i> , 2016, 30, 233-244.	2.8	63
61	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-FCVAD) with or without blinatumomab versus standard intensive chemotherapy (FCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586.	2.0	63
62	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	61
63	Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 233-233.	0.6	60
64	ATM gene deletion in patients with adult acute lymphoblastic leukemia. , 2000, 88, 1057-1062.		54
65	Chronic Myelogenous Leukemia, Version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1327-1340.	2.3	52
66	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Future Oncology</i> , 2020, 16, 517-523.	1.1	52
67	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467.	2.0	49
68	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3327-3338.	0.6	47
69	Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 1991, 68, 1201-1207.	2.0	45
70	Duvelisib, an oral dual PI3K/Î³ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. <i>American Journal of Hematology</i> , 2018, 93, 1318-1326.	2.0	45
71	Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. <i>Cancer</i> , 1993, 72, 2155-2160.	2.0	43
72	Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. <i>Cancer</i> , 2018, 124, 1722-1732.	2.0	43

#	ARTICLE	IF	CITATIONS
73	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	2.2	43
74	Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. <i>Lancet Haematology</i> , 2018, 5, e136-e146.	2.2	42
75	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020, 97, 106432.	0.4	40
76	Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 135-141.	0.2	37
77	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. <i>American Journal of Hematology</i> , 2015, 90, 193-196.	2.0	35
78	The absolute percent deviation of IGHV mutation rather than a 98% cutoff predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. <i>British Journal of Haematology</i> , 2018, 180, 33-40.	1.2	33
79	Significance of recurrence of minimal residual disease detected by multiparameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. <i>American Journal of Hematology</i> , 2017, 92, 279-285.	2.0	32
80	Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. <i>Investigational New Drugs</i> , 1999, 17, 89-95.	1.2	31
81	Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e314-e322.	1.8	28
82	Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. <i>British Journal of Haematology</i> , 2022, 196, 947-953.	1.2	28
83	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. <i>American Journal of Hematology</i> , 2015, 90, 769-773.	2.0	27
84	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	2.0	27
85	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 720704.	1.3	27
86	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 1388-1395.	2.0	26
87	Survival of Young Patients with Chronic Lymphocytic Leukemia Failing Fludarabine Therapy: A Basis for the Use of Myeloablative Therapies. <i>Leukemia and Lymphoma</i> , 1995, 18, 493-496.	0.6	25
88	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150.	2.0	25
89	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021, 35, 3201-3211.	3.3	25
90	Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2000, 96, 768-770.	0.6	25

#	ARTICLE	IF	CITATIONS
91	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	2.0	24
92	Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> (<i>MLL</i>) rearrangement: the MD Anderson experience. <i>Blood Advances</i> , 2021, 5, 5415-5419.	2.5	24
93	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 3331-3331.	0.6	24
94	Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. <i>Future Oncology</i> , 2019, 15, 579-589.	1.1	23
95	Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, Vencabrutinib, in B-Cell Malignancies. <i>Blood</i> , 2019, 134, 3041-3041.	0.6	23
96	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	3.3	22
97	Novel Treatments for Chronic Lymphocytic Leukemia and Moving Forward. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e317-e325.	1.8	17
98	Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 3033-3037.	2.5	16
99	Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. <i>Blood</i> , 2021, 138, 2810-2827.	0.6	16
100	Novel agents in chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2016, 2016, 137-145.	0.9	14
101	Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. <i>Blood</i> , 2019, 134, 357-357.	0.6	14
102	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. <i>Blood</i> , 2019, 134, 2723-2723.	0.6	14
103	Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 580-591.	1.8	13
104	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 3721-3721.	0.6	13
105	Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 823-823.	0.6	12
106	A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 395-400.e1.	0.2	11
107	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. <i>American Journal of Hematology</i> , 2019, 94, 408-416.	2.0	11
108	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. <i>Blood</i> , 2016, 128, 588-588.	0.6	11

#	ARTICLE	IF	CITATIONS
109	Hyper-CDVAD plus ofatumumab versus hyper-CDVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2021, 127, 3381-3389.	2.0	10
110	B cell receptor inhibition as a target for CLL therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 2-14.	0.7	9
111	The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1079-1088.	1.0	9
112	A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. <i>British Journal of Haematology</i> , 2019, 185, 606-608.	1.2	8
113	Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. <i>Expert Review of Hematology</i> , 2020, 13, 871-883.	1.0	8
114	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3278-3282.	0.6	7
115	Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 31-38.	1.0	5
116	Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD). <i>Blood</i> , 2019, 134, 1299-1299.	0.6	4
117	Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing ibrutinib. <i>Blood</i> , 2016, 128, 4390-4390.	0.6	4
118	Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population. <i>Leukemia and Lymphoma</i> , 2022, 63, 2992-2995.	0.6	4
119	Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories. <i>Blood</i> , 2019, 134, 1344-1344.	0.6	3
120	A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy. <i>Blood</i> , 2019, 134, 2927-2927.	0.6	3
121	Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2015, 90, 967-969.	2.0	2
122	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. <i>Blood</i> , 2019, 134, 2582-2582.	0.6	2
123	First-line therapy for young patients with CLL. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 146-148.	0.9	1
124	MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL. <i>Leukemia and Lymphoma</i> , 2017, 58, 1498-1501.	0.6	1
125	ATM gene deletion in patients with adult acute lymphoblastic leukemia. <i>Leukemia</i> , 2000, 88, 1057.		1
126	Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 2548-2548.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
128	Clinical implications of the 2018 iwCLL Guidelines update. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16 Suppl 15, 1-16.	0.3	0
129	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1580-1588.	0.6	0